Compare
Veracyte, Inc. vs CareDx, Inc. vs Castle Biosciences Inc vs Caris Life Sciences, Inc.
| Latest fiscal year | Veracyte, Inc. VCYT | CareDx, Inc. CDNA | Castle Biosciences Inc CSTL | Caris Life Sciences, Inc. CAI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $517.14M | $379.81M | $344.23M | $812.03M |
| Revenue growth (YoY) | +16.0% | +13.8% | +3.7% | +97.0% |
| Gross margin | 70.1% | n/a | 79.4% (computed) | n/a |
| Operating margin | 11.2% | -8.1% | -12.4% | 5.6% |
| Net margin | 12.8% | -5.6% | -7.0% | -8.4% |
| Net income | $66.35M | -$21.35M | -$24.16M | -$68.09M |
| EPS (Diluted) | $0.82 | -$0.40 | -$0.83 | -$3.22 |
| Operating cash flow | $136.31M | $42.03M | $64.35M | $83.16M |
| Free cash flow | $126.63M | n/a | $28.33M | $66.89M |
| Cash & equivalents | $362.58M | $65.43M | $116.73M | $796.27M |
| Total assets | $1.41B | $413.23M | $578.56M | $1.13B |
| Total liabilities | $96.44M | $110.13M | $107.68M | $548.36M |
| Shareholders' equity | $1.31B | $303.10M | $470.87M | $577.31M |
| Return on year-end equity | 5.1% | -7.0% | -5.1% | -11.8% |
| Shares outstanding | 79.36M | 50.92M | 29.69M | 282.53M |
Revenue, most recent five fiscal years
| Fiscal year | Veracyte, Inc. | CareDx, Inc. | Castle Biosciences Inc | Caris Life Sciences, Inc. |
|---|---|---|---|---|
| Latest | $517.14M Ended 2025-12-31 | $379.81M Ended 2025-12-31 | $344.23M Ended 2025-12-31 | $812.03M Ended 2025-12-31 |
| 1 year earlier | $445.76M Ended 2024-12-31 | $333.79M Ended 2024-12-31 | $332.07M Ended 2024-12-31 | $412.26M Ended 2024-12-31 |
| 2 years earlier | $361.05M Ended 2023-12-31 | $280.32M Ended 2023-12-31 | $219.79M Ended 2023-12-31 | $306.13M Ended 2023-12-31 |
| 3 years earlier | $296.54M Ended 2022-12-31 | $321.79M Ended 2022-12-31 | $137.04M Ended 2022-12-31 | n/a |
| 4 years earlier | $219.51M Ended 2021-12-31 | $296.40M Ended 2021-12-31 | $94.08M Ended 2021-12-31 | n/a |